COVID-19 Vaccine Development

A global pharmaceutical company wanted to enroll representative cohorts of diverse populations in support of its work to develop a vaccine for COVID-19 in the United States. Faced with poor enrollment among non-white patients (only 24% of total enrollees), recruitment and enrollment activity was paused in August of 2020. After pausing all recruitment and enrollment activities in August 2020, Trialbee helped the sponsor to reach its enrollment representation goals just two months later.

To learn more about Trialbee, visit their Clinical Leader page.